[Translation] An open, multicenter, Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of ASKC202 tablets or ASK120067 tablets in patients with advanced solid tumors

主要目的评价ASKC202片单、多次给药在晚期实体瘤患者中的安全性和耐受性，确定 ASKC202片的剂量限制性毒性（DLT）和最大耐受剂量（MTD）。评价ASKC202片联合ASK120067片在局部晚期或转移性非小细胞肺癌（NSCLC）患者中的安全性和耐受性，确定ASKC202 片联合 ASK120067片的剂量限制性毒性（DLT）和最大耐受剂量（MTD）。次要目的评价ASKC202 片在晚期实体瘤患者中的药代动力学特征；评价ASKC202片在晚期实体瘤患者中的初步抗肿瘤疗效，为确定后续临床研究给药方案提供依据。评价ASKC202片联合ASK120067片在局部晚期或转移性NSCLC患者中的药代动力学特征；评价ASKC202片联合ASK120067片在局部晚期或转移性NSCLC患者中的初步抗肿瘤疗效，为确定后续临床研究给药方案提供依据。

[Translation]

Main purpose To evaluate the safety and tolerability of single and multiple administrations of ASKC202 tablets in patients with advanced solid tumors, and to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of ASKC202 tablets. To evaluate the safety and tolerability of ASKC202 tablets combined with ASK120067 tablets in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), and to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of ASKC202 tablets combined with ASK120067 tablets. Secondary purpose To evaluate the pharmacokinetic characteristics of ASKC202 tablets in patients with advanced solid tumors; to evaluate the preliminary anti-tumor efficacy of ASKC202 tablets in patients with advanced solid tumors, and to provide a basis for determining the dosing regimen for subsequent clinical studies. To evaluate the pharmacokinetic characteristics of ASKC202 tablets combined with ASK120067 tablets in patients with locally advanced or metastatic NSCLC; to evaluate the preliminary anti-tumor efficacy of ASKC202 tablets combined with ASK120067 tablets in patients with locally advanced or metastatic NSCLC, and to provide a basis for determining the dosing regimen for subsequent clinical studies.

Start Date02 Aug 2022

Sponsor / Collaborator

Jiangsu Aosaikang Pharmaceutical Co. Ltd.

NCT05631678

/ CompletedPhase 1

An Open-lable, Two- Period, Single-sequence, Self-controlled Study to Evaluate the Effect of Oral Rifampicin or Itraconazole on the Pharmacokinetics of ASK120067 Tablets

To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects.
To evaluate the safety of ASK120067 tablets or combination with rifampicin capsules or itraconazole capsules in healthy subjects.

Start Date06 Jun 2022

Sponsor / Collaborator

Jiangsu Aosaikang Pharmaceutical Co. Ltd.

CTR20221327

/ CompletedPhase 1

开放、两周期、单序列、自身对照研究设计，评价口服利福平或伊曲康唑对ASK120067片药代动力学的影响

[Translation] An open-label, two-period, single-sequence, self-controlled study design to evaluate the effect of oral rifampicin or itraconazole on the pharmacokinetics of ASK120067 tablets

主要目的：评价健康受试者口服CYP3A4强诱导剂利福平胶囊、强抑制剂伊曲康唑胶囊对ASK120067及其代谢产物CCB4580030药代动力学的影响；次要目的：评价健康受试者单剂量口服ASK120067片及与利福平胶囊、伊曲康唑胶囊联合用药的安全性。

[Translation]

Primary objective: To evaluate the effects of oral administration of rifampicin capsules, a strong CYP3A4 inducer, and itraconazole capsules, a strong inhibitor, on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects; Secondary objective: To evaluate the safety of single-dose oral administration of ASK120067 tablets and its combination with rifampicin capsules and itraconazole capsules in healthy subjects.

Start Date06 Jun 2022

Sponsor / Collaborator

Gibh

[+2]

100 Clinical Results associated with Limertinib

100 Translational Medicine associated with Limertinib

100 Patents (Medical) associated with Limertinib

Literatures (Medical) associated with Limertinib

27 May 2024·JACS Au

AM-DMF-SCP: Integrated Single-Cell Proteomics Analysis on an Active Matrix Digital Microfluidic Chip

Article

Author: Wang, Yuqiu ; Pan, Zilu ; Ma, Hanbin ; Hu, Siyi ; Jin, Kai ; Shi, Mude ; Zhou, Hu ; Chen, Yimin ; Chen, Hongxu ; Yang, Zhicheng ; Feng, Fang ; Liu, Qian ; Xie, Hua

Single-cell proteomics offers unparalleled insights into cellular diversity and molecular mechanisms, enabling a deeper understanding of complex biological processes at the individual cell level. Here, we develop an integrated sample processing on an active-matrix digital microfluidic chip for single-cell proteomics (AM-DMF-SCP). Employing the AM-DMF-SCP approach and data-independent acquisition (DIA), we identify an average of 2258 protein groups in single HeLa cells within 15 min of the liquid chromatography gradient. We performed comparative analyses of three tumor cell lines: HeLa, A549, and HepG2, and machine learning was utilized to identify the unique features of these cell lines. Applying the AM-DMF-SCP to characterize the proteomes of a third-generation EGFR inhibitor, ASK120067-resistant cells (67R) and their parental NCI-H1975 cells, we observed a potential correlation between elevated VIM expression and 67R resistance, which is consistent with the findings from bulk sample analyses. These results suggest that AM-DMF-SCP is an automated, robust, and sensitive platform for single-cell proteomics and demonstrate the potential for providing valuable insights into cellular mechanisms.

01 Oct 2023·Clinical pharmacology in drug development

Effect of Food on the Pharmacokinetics of Limertinib (ASK120067) and its Main Metabolite in Healthy Chinese Volunteers.

Article

Author: Jiang, Bo ; Chen, Wenjun ; Lou, Honggang ; Guo, Haifang ; Jiang, Qianqian ; Ruan, Zourong ; Yang, Dandan

Limertinib (ASK120067) is a newly developed third-generation epidermal growth factor receptor tyrosine kinase inhibitor. This phase I, open-label, 2-period crossover study was conducted to evaluate the effect of food on the pharmacokinetics (PK) of limertinib and its active metabolite CCB4580030 in Chinese healthy volunteers (HVs). HVs were randomly assigned (1:1) to receive a single dose of limertinib (160 mg) under the fasted state in period 1 and fed condition in period 2, or vice versa. Twenty-four HVs were enrolled, and 20 HVs completed both study periods. PK were assessed before dosing and ≤72 hours after dosing. PK parameters were analyzed by a noncompartmental method. Limertinib was absorbed faster in the fasted state compared with the fed state. The geometric mean ratios (fed/fast) of maximum concentration, area under the plasma concentration-time curve from time 0 to the last quantifiable concentration, and area under the plasma concentration-time curve from time 0 to infinity for ASK120067 were 145.5%, 145.4%, and 141.9%, respectively. Geometric mean ratios of the PK parameters of CCB4580030 were >125.00% and 90% confidence intervals were outside the preset bioequivalent range. Safety profiles were similar in both prandial states, and limertinib was well tolerated. Food reduced the rate and increased the extent of limertinib absorption following oral administration. Whether limertinib can be administered regardless of prandial state in patients warrants further investigation of efficacy and safety.

02 Sep 2023·Expert Opinion on Drug Metabolism & Toxicology

Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects

Article

Author: Guo, Haifang ; Ma, Tingting ; Cao, Bei ; Geng, Yan ; Zhao, Yu ; Liu, Ming ; Huang, Lei ; Yang, Yuanxun ; Lin, Hui ; Li, Juan

BACKGROUNDLimertinib is a novel mutant-selective and irreversible inhibitor of the epidermal growth factor receptor under development. A phase 1 open, two-period, single-sequence, self-controlled, two-part study was initiated to characterize the effects of a strong CYP3A4 inducer (rifampin) or inhibitor (itraconazole) on the pharmacokinetics of limertinib.RESEARCH DESIGN AND METHODSTwenty-four healthy subjects in each part received a single dose of limertinib alone (160 mg, Part A; 80 mg, Part B) and with multiple doses of rifampin 600 mg once daily (Part A) or itraconazole 200 mg twice daily (Part B).RESULTSCoadministration of rifampin decreased exposure (area under the plasma concentration-time curve from time 0 to infinity, AUC_0-inf) of limertinib and its active metabolite CCB4580030 by 87.86% (geometric least-squares mean [GLSM] ratio, 12.14%; 90% confidence interval [CI], 9.89-14.92) and 66.82% (GLSM ratio, 33.18%; 90% CI, 27.72-39.72), respectively. Coadministration of itraconazole increased the AUC_0-inf of limertinib by 289.8% (GLSM ratio, 389.8%; 90% CI, 334.07-454.82), but decreased that of CCB4580030 by 35.96% (GLSM ratio, 64.04%; 90% CI, 50.78-80.77).CONCLUSIONSOur study demonstrates that the concomitant use of limertinib with strong CYP3A inducers or inhibitors is not recommended. A single dose of limertinib, administered with or without rifampin or itraconazole, is generally safe and well tolerated in healthy Chinese subjects.CLINICAL TRIAL REGISTRATIONwww.clinicaltrials.gov identifier is NCT05631678.

News (Medical) associated with Limertinib

17 Jan 2025

·www.prnewswire.com

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm, 002755.SZ), jointly announce that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC). Limertinib is the 14th product in Innovent's commercial portfolio and represents a cutting-edge addition to its strong TKI franchise, offering an innovative precision therapy option to lung cancer patients. A Phase 2b pivotal study evaluating 301 patients with locally advanced or metastatic EGFR T790M-mutated NSCLC demonstrated limertinib's robust efficacy and safety profile. Independent review committee（IRC） assessment showed an overall response rate (ORR) of 68.8% and a disease control rate (DCR) of 92.4%. The median progression-free survival (PFS) reached 11.0 months, with a median duration of response (DoR) of 11.1 months. For patients with assessable central nervous system (CNS) lesions (N=99), the CNS best-ORR was 65.9% with a median PFS of 10.6 months. The safety profile aligned with other EGFR-targeting agents in its class. Additionally, limertinib met its primary endpoint in a Phase 3 clinical trial comparing it to gefitinib for first-line treatment of locally advanced or metastatic NSCLC harboring EGFR mutations. A separate NDA for the first-line treatment in adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations is currently under NMPA review. "Limertinib has demonstrated significant efficacy and safety in NSCLC patients with EGFR T790M mutation and EGFR-sensitive mutations. Patients treated with limertinib showed a reduced risk of CNS progression or death. This approval brings new hope and options to patients with advanced EGFR-mutated NSCLC in China," said Professor Shi Yuankai, MD, Department of Medical Oncology at Chinese Academy of Medical Sciences and Principal Investigator of the Phase 2b and Phase 3 clinical studies. Dr. Hui Zhou, Senior Vice President of Innovent, stated："The approval of limertinib's first indication marks a significant milestone, providing new treatment options for T790 mutation-positive lung cancer patients who have progressed after previous EGFR-TKI treatments. We anticipate the first-line treatment indication will benefit even more patients in the near future. As our 14th commercial product, limertinib represents an important advancement in precision medicine for lung cancer. We look forward to working with ASK Pharm to bring limertinib to market and benefit Chinese patients with EGFR-mutated NSCLC." Mr. Jingfei Ma, CEO and Executive Director of ASK Pharm, stated: "Beyond the approval for EGFR T790M+ NSCLC, limertinib is also under regulatory review for first-line treatment of EGFR 19DEL+ or L858R+ NSCLC in China. ASKC202, a new highly selective c-Met inhibitor, is currently undergoing clinical study in combination with limertinib to treat patients with third-generation EGFR-TKI resistance. Together with Innovent, we look forward to limertinib benefiting more Chinese lung cancer patients in the near future. The first approval of limertinib, a Class I innovative product, represents significant progress in the company's transformation toward innovative drug research and development. " About EGFR mutation-positive non-small-cell lung cancer (NSCLC) Lung cancer remains one of the deadliest and most common cancers globally[i], with NSCLC accounting for about 85% of cases. Around 70% of NSCLC patients are diagnosed at locally advanced or metastatic disease stages that cannot be surgically resected. EGFR mutations are particularly prevalent in Asian NSCLC patients, affecting 30% to 50% of cases. EGFR-TKIs are the recommended first-line standard of care for this group, with third-generation EGFR inhibitors offering the broadest applicability. About Limertinib Limertinib is an orally-administrated, third-generation EGFR TKI with proprietary rights, approved by the China's NMPA for the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC). A second NDA is under NMPA review for first-line treatment of adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations. The drug demonstrated success in a multi-center, randomized, double-blind, controlled Phase 3 clinical trial comparing its efficacy and safety of to gefitinib in first-line treatment of patients with locally advanced or metastatic NSCLC harboring EGFR mutations. With the primary endpoint met, results will be presented at upcoming academic conferences or published in academic journals. In October 2024, Innovent and ASK Pharm entered into a strategic collaboration and license agreement for limertinib in Mainland China. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 14 products in the market. It has 3 new drug applications (NDA) under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. About Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) Founded in January 2003, Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) is a research-based pharmaceutical enterprise that integrates and streamlines innovative research and development with manufacture, marketing promotion and sales of proprietary pharmaceuticals, fine chemicals and health-care products. ASK Pharm specializes in digestive disease, multidrug resistant infection, oncology and chronic disease areas. ASK Pharm focuses on the R&D of small-molecule targeted innovative drugs and immuno-oncology biologic drugs. Currently, there are 48 major research projects, including 11 disclosed key projects focused on innovative chemical and biologic drugs. Among these, the innovative anti-tumor drug Limertinib are in the NDA stage, while ASKC109 (maltol iron capsules) and ASKB589 (Claudin18.2 monoclonal antibody) are in Phase III clinical trials. ASK Pharm has Ranked among the top 20 best industrial enterprises in China's pharmaceutical R&D pipeline for 14 consecutive years and it has also received numerous honors such as "Top Ten National R&D Innovators", "Best National Enterprise for Investment", and "National Torch Program High-Tech Enterprises". For more information, visit . Innovent's Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Reference SOURCE Innovent Biologics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 2Phase 3License out/inDrug Approval

09 Oct 2024

·www.pharmaceutical-technology.com

FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants

The company had sought approval for dasiglucagon for the treatment and prevention of hypoglycaemia in infants with congenital hyperinsulinism. Credit: Gorodenkoff/Shutterstock. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Zealand Pharma , declining the approval of dasiglucagon for the treatment and prevention of hypoglycaemia in infants with congenital hyperinsulinism (CHI). The CRL, which pertains to Part 1 of the new drug application (NDA) for patients aged seven days and older, cites the need for a reinspection at a third-party manufacturing facility. This regulatory decision is linked to the timing of a reinspection at a contract manufacturing site that concluded in August/September 2024. The facility, responsible for producing dasiglucagon, has not received its inspection classification post-reinspection. Although a previous inspection had identified deficiencies, they were not related to dasiglucagon and had been addressed by the time of the latest reinspection. See Also: Clinical Dose Companies in Contract Manufacturing for the Pharmaceutical Industry Innovent and ASK Pharm to commercialise limertinib for lung cancer The CRL did not raise any concerns regarding the clinical data or the safety profile of dasiglucagon. Zealand Pharma’s NDA for dasiglucagon is currently undergoing a two-part regulatory review. While Part 1 involved dosing for up to three weeks, Part 2 will cover usage beyond that period. The FDA has requested additional analyses from existing continuous glucose monitoring data collected during Phase III clinical trials to support the use of dasiglucagon in CHI for extended periods. Zealand Pharma anticipates submitting the required data by the end of 2024. Zealand Pharma chief medical officer David Kendall said: “We at Zealand Pharma are acutely aware of the significant unmet medical need for newborns and children with congenital hyperinsulinism who have either no or very limited treatment options today. “We are committed to working with the FDA and our third-party manufacturing partner to bring dasiglucagon to patients living with this devastating disease in the months ahead.”

NDAPhase 3

09 Oct 2024

·www.pharmaceutical-technology.com

MSD ventures into fibroblast therapies with $1.9bn deal with Mestag

Mestag’s pipeline consists of antibody therapies based on fibroblast-immune interactions as a treatment for cancer and inflammatory diseases. Image credit: Sergiy Palamarchuk / Shutterstock. MSD ( Merck & Co) has signed a license and collaboration agreement with Mestag Therapeutics to develop new fibroblast therapies for inflammatory diseases – a deal potentially worth $1.9bn The companies did not disclose the particulars of the deal, noting that the agreement allows MSD the option to get exclusive development and marketing licences to “a prespecified number of potential targets.” The UK-based biotech in return will receive an upfront payment, and access fees and will be in line to receive option fees and “downstream payments”. Fibroblasts form the connective tissue and are responsible for synthesising extracellular matrix components and collagen, the structural framework of the body. They also play an important role in wound healing, inflammation, and tissue repair. Mestag’s pipeline consists of antibody therapies based on fibroblast-immune interactions as a treatment for cancer and inflammatory diseases. The company’s lead candidate, MST-0300, is a bispecific antibody. The therapy targets lymphotoxin beta receptor (LTBR) in the tumour on co-engagement of fibroblast activation protein (FAP), a tumour-specific marker expressed by cancer-associated fibroblasts, to induce the formation of tertiary lymphoid structures (TLSs) in solid tumours. The presence of these TLSs can be predictive of improved patient outcomes and better therapeutic response. Mestag plans to file an investigational new drug (IND) application in the second half of 2025. Another preclinical candidate in the company’s pipeline is M402, a stromal checkpoint agonist antibody. The therapy is designed to inhibit specific immune cell populations, including myeloid cells. Mestag states that M402 has the “potential to benefit patients across inflammatory diseases including rheumatoid arthritis, lupus, Sjogren’s, graft-versus-host disease and others.” See Also: Clinical Dose Companies in Contract Manufacturing for the Pharmaceutical Industry Innovent and ASK Pharm to commercialise limertinib for lung cancer MSD has been steadily investing in expanding its antibody therapies pipeline. In August, the company acquired Curon Biopharmaceutical , a Chinese biopharmaceutical company specialising in developing bispecific antibodies. The deal is worth approximately $1.3bn in upfront and milestone-based payments. Mestag had previously collaborated with Johnson & Johnson (J&J) in 2021. The licensing agreement allowed J&J the option of an exclusive license to develop and commercialise up to two therapies for the treatment of inflammatory disease.

License out/inADCAcquisitionImmunotherapy

100 Deals associated with Limertinib

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16087

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma	CN	Jiangsu Aosaikang Pharmaceutical Co. Ltd.	14 Jan 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer	NDA/BLA	CN	Jiangsu Aosaikang Pharmaceutical Co. Ltd.	13 Aug 2024
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer	NDA/BLA	CN	Jiangsu Aosaikang Pharmaceutical Co. Ltd.	13 Aug 2024
EGFR positive non-small cell lung cancer	Phase 3	CN	Gibh	30 Oct 2019
EGFR positive non-small cell lung cancer	Phase 3	CN	Jiangsu Aosaikang Pharmaceutical Co. Ltd.	30 Oct 2019
EGFR positive non-small cell lung cancer	Phase 3	CN	Shanghai Institute of Materia Medica Chinese Academy of Sci	30 Oct 2019
metastatic non-small cell lung cancer	Phase 3	CN	Jiangsu Aosaikang Pharmaceutical Co. Ltd.	23 Jul 2019
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 2	CN	Shanghai Institute of Materia Medica Chinese Academy of Sci	03 Jan 2018
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 2	CN	Gibh	03 Jan 2018
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 2	CN	Jiangsu Aosaikang Pharmaceutical Co. Ltd.	03 Jan 2018
MET gene amplification Non-small Cell Lung Cancer	IND Approval	CN	Jiangsu Aosaikang Pharmaceutical Co. Ltd.	20 Nov 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03502850 (ASCO2022) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer EGFR T790M Mutation	301	Limertinib	(foyepdhhuc) = fylptjarmq tfxmtrnkrv (ueqqfbieyk, 63.2 - 74.0) View more	Positive	02 Jun 2022
				Limertinib (CNS metastases)	(foyepdhhuc) = amuxbvpinp tfxmtrnkrv (ueqqfbieyk, 54.4 - 74.0) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis